Braidwell LP Acquires New Position in Oculis Holding AG $OCS

Braidwell LP bought a new position in Oculis Holding AG (NASDAQ:OCS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 834,183 shares of the company’s stock, valued at approximately $11,570,000.

A number of other institutional investors also recently modified their holdings of OCS. Perceptive Advisors LLC purchased a new position in shares of Oculis during the 4th quarter valued at $9,862,000. SR One Capital Management LP raised its holdings in shares of Oculis by 98.8% during the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after acquiring an additional 318,522 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in Oculis by 152.3% during the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after purchasing an additional 200,000 shares during the last quarter. Folketrygdfondet acquired a new stake in Oculis during the fourth quarter valued at $3,651,000. Finally, Propel Bio Management LLC purchased a new position in Oculis in the fourth quarter valued at about $3,452,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Stock Performance

OCS opened at $12.02 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35. The company has a market cap of $696.92 million, a PE ratio of -6.91 and a beta of 0.52. The stock has a 50-day moving average of $12.59 and a 200-day moving average of $20.39. Oculis Holding AG has a 52-week low of $10.52 and a 52-week high of $34.47.

Oculis (NASDAQ:OCS) last posted its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $0.38 million during the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. As a group, equities research analysts forecast that Oculis Holding AG will post -2.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Guggenheim dropped their target price on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Oculis in a research note on Tuesday, August 25th. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Needham & Company LLC reduced their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oculis has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Oculis Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.